These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 37118734)

  • 1. Apoptosis related genes mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide immunotherapy in bladder cancer.
    Zhou L; Xu G; Huang F; Chen W; Zhang J; Tang Y
    BMC Med Genomics; 2023 Apr; 16(1):88. PubMed ID: 37118734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
    Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
    Front Immunol; 2022; 13():964393. PubMed ID: 36211344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
    Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
    Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
    Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
    Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
    Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
    Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes.
    Zhao H; Chen Z; Fang Y; Su M; Xu Y; Wang Z; Gyamfi MA; Zhao J
    J Immunol Res; 2022; 2022():1793005. PubMed ID: 35450397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
    Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
    Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A risk model based on pyroptosis subtypes predicts tumor immune microenvironment and guides chemotherapy and immunotherapy in bladder cancer.
    Wu T; Li S; Yu C; Wu Y; Long H
    Sci Rep; 2022 Dec; 12(1):21467. PubMed ID: 36509838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
    Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer.
    Liu R; Yang T; Huang J; Xiao Z; Liu J; Li Z; Tong S
    BMC Cancer; 2024 Aug; 24(1):947. PubMed ID: 39095785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
    Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
    BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive analysis of immunogenic cell death and its key gene HSP90AA1 in bladder cancer.
    Song Q; Zhou Z; Bai J; Liu N
    Clin Transl Oncol; 2023 Aug; 25(8):2587-2606. PubMed ID: 37000291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia is correlated with the tumor immune microenvironment: Potential application of immunotherapy in bladder cancer.
    Chen H; Zhang Y; Chen X; Xu R; Zhu Y; He D; Cheng Y; Wang Z; Qing X; Cao K
    Cancer Med; 2023 Dec; 12(24):22333-22353. PubMed ID: 38063246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
    Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
    Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.
    Hu J; Othmane B; Yu A; Li H; Cai Z; Chen X; Ren W; Chen J; Zu X
    BMC Med; 2021 Nov; 19(1):289. PubMed ID: 34836536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
    Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
    Front Immunol; 2022; 13():965469. PubMed ID: 36090967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generalized machine learning based on multi-omics data to profile the effect of ferroptosis pathway on prognosis and immunotherapy response in patients with bladder cancer.
    Liu X; Qiu Z; Zhang X; Su Z; Yi R; Zou D; Xie C; Jin N; Long W; Liu X
    Environ Toxicol; 2024 Feb; 39(2):680-694. PubMed ID: 37647346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer.
    Song Q; Zhou R; Shu F; Fu W
    Front Immunol; 2022; 13():958368. PubMed ID: 35990642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing and experimental validating a B cell exhaustion-related gene signature to assess prognosis and immunotherapeutic response in bladder cancer.
    Zhou R; Zhou J; Deng S; Zhu Y; Muhuitijiang B; Wu J; Tan W
    Gene; 2024 Nov; 927():148634. PubMed ID: 38848880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of Muscle Invasive Bladder Cancer to Predict Prognosis of Patients Treated with Immunotherapy.
    Wang Z; Li X; Wang X; Liu J; Wang L; Wei W; Duan X; Ding D
    J Immunol Res; 2022; 2022():6737241. PubMed ID: 35677536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.